Screening for Hereditary Transthyretin Amyloidosis in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (hATTR IN CIDP)


The purpose of this research study is to determine if some people diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) may have another genetic disease that can cause nerve damage, called hereditary TTR amyloidosis (hATTR). hATTR is treated very differently than CIDP, so understanding if hATTR is sometimes incorrectly diagnosed as CIDP is important.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 120

Inclusion criteria:

You are eligible for this study if you are:

1. Age 18-years or older.
2. Have a clinical diagnosis of CIDP by a neuromuscular specialist.
3. Are seeing for your disease in the University of Calgary Neuromuscular Clinic.

Exclusion criteria:

You are not eligible for this study if you are:

1. Unable to understand the informed consent process due to cognitive or language barriers.


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Dr. Gordon Jewett

Principal investigator:

Gordon Jewett

Clinical trial: